Added to YB: 2025-04-04
Pitch date: 2025-04-03
TEVA [bullish]
Teva Pharmaceutical Industries Limited
+105.17%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$30.7B
Pitch Price
$14.52
Price Target
36.51 (+23%)
Dividend
N/A
EV/EBITDA
9.65
P/E
43.30
EV/Sales
2.72
Sector
Pharmaceuticals
Category
turnaround
Update on Teva Pharmaceuticals ($TEVA): Still a value opportunity while the company is rebuilding
TEVA: Undervalued at 5.8x 2025 EPS. Margin expansion plan to offset g-Revlimid LOE. Strong branded portfolio (Austedo, Ajovy, Uzedy). Promising pipeline with duvakitug. 8.7% earnings CAGR 2025-2029. FCF yield to 16.7% by 2029. Debt reduction. Litigation settled. Key risks: LOE impact, execution.
Read full article (4 min)